ArticleEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin2024
The potential of federated learning for public health purposes: a qualitative analysis of GDPR compliance, Europe, 2021.
Article in Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Federated Learning in Endodontics: A Framework for Privacy-Preserving Multicentre Artificial Intelligence.International dental journal · 2026Review
- Federated learning's uncomfortable truth: why human networks matter more than neural networks.Journal of the American Medical Informatics Association : JAMIA · 2026Article
- Flexible wearable medical devices: from material innovations and data processing to intelligent healthcare applications.Journal of advanced research · 2026Review
- Combining federated learning and travelling model boosts performance and opens opportunities for digital health equity.NPJ digital medicine · 2026Article
- Federated, governed, and interoperable? The emerging architecture of public human genomic data infrastructures: a European perspective.Frontiers in genetics · 2026Review
- Federated Learning in Public Health: A Systematic Review of Decentralized, Equitable, and Secure Disease Prevention Approaches.Healthcare (Basel, Switzerland) · 2025Review
- Technical and legal aspects of federated learning in bioinformatics: applications, challenges and opportunities.Frontiers in digital health · 2025Review
- Towards generalizable Federated Learning in medical imaging: A real-world case study on mammography data.Computational and structural biotechnology journal · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BackgroundThe wide application of machine learning (ML) holds great potential to improve public health by supporting data analysis informing policy and practice. Its application, however, is often hampered by data fragmentation across organisations and strict regulation by the General Data Protection Regulation (GDPR). Federated learning (FL), as a decentralised approach to ML, has received considerable interest as a means to overcome the fragmentation of data, but it is yet unclear to which extent this approach complies with the GDPR.AimOur aim was to understand the potential data protection implications of the use of federated learning for public health purposes.MethodsBuilding upon semi-structured interviews (n = 14) and a panel discussion (n = 5) with key opinion leaders in Europe, including both FL and GDPR experts, we explored how GDPR principles would apply to the implementation of FL within public health.ResultsWhereas this study found that FL offers substantial benefits such as data minimisation, storage limitation and effective mitigation of many of the privacy risks of sharing personal data, it also identified various challenges. These challenges mostly relate to the increased difficulty of checking data at the source and the limited understanding of potential adverse outcomes of the technology.ConclusionSince FL is still in its early phase and under rapid development, it is expected that knowledge on its impracticalities will increase rapidly, potentially addressing remaining challenges. In the meantime, this study reflects on the potential of FL to align with data protection objectives and offers guidance on GDPR compliance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.